Viridian Therapeutics ( (VRDN) ) just unveiled an announcement.
Viridian Therapeutics’ phase 3 THRIVE trial for their drug veligrotug has yielded highly positive outcomes, meeting all primary and secondary endpoints and demonstrating significant improvements in patients with thyroid eye disease (TED). With rapid onset of action and favorable safety profile, veligrotug could offer a more convenient treatment for TED. Further trials are ongoing, with plans for a biologics license application in the second half of 2025, indicating potential for veligrotug to become a leading treatment option.
For a thorough assessment of VRDN stock, go to TipRanks’ Stock Analysis page.
